Dr. Stefan Gruenwald's career in Life Sciences spans more than two decades. He received his M.D. and Ph.D. at the Johann-Wolfgang Goethe University in Frankfurt, Germany. He later completed post-doctoral research at the Scripps Research Institute and the University of California San Diego. He is fluent in English and German.
In 1991 Stefan Gruenwald joined the newly formed PharMingen (now a part of BD Bioscience), which has become one of the most successful San Diego based biotech companies. At PharMingen, Dr. Gruenwald established and maintained a research team of 155 scientists. His R&D lab cloned over 1,300 genes and expressed more than 200 proteins in various protein expression systems. Dr. Gruenwald holds three patents, based on technologies developed at PharMingen.
Most recently, he has specialized in M&A within the life sciences arena. In 1997, he was instrumental in the $75M sale of PharMingen to Fortune 100 Company, Becton Dickinson. In 2000, Dr. Gruenwald co-founded Orbigen, a San Diego based proteomics company. Orbigen developed over 3,000 products in a dozen different lines ranging from proteomics to immunology. In 2004, Dr. Gruenwald was crucial in negotiating the merger between Orbigen and Jingmei, the second largest Biotech reagent company in China.
Through Dr. Gruenwald's vast resource of scientific and business contacts, he is able to provide opportunities otherwise unavailable to most small to medium sized companies. His understanding of high-technology has made him a valuable partner to many Wall Street money managers and has granted him access to several billion USD hedge funds and VC / private equity funds worldwide.